J&J’s Prezista Approved For Treatment-Resistant HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
The protease inhibitor – formerly known as TMC-114 – is to be co-administered with a low dose of ritonavir.
You may also be interested in...
J&J’s Intelence Approved For HIV Treatment In NNRTI-Resistant Patients
Johnson & Johnson’s Tibotec unit prices etravirine at wholesale acquisition cost of $5.45, firm tells “The Pink Sheet” DAILY.
J&J’s Intelence Approved For HIV Treatment In NNRTI-Resistant Patients
Johnson & Johnson’s Tibotec unit prices etravirine at wholesale acquisition cost of $5.45, firm tells “The Pink Sheet” DAILY.
J&J’s HIV Therapy Etravirine Shown To Have Antiviral Activity In Phase III Studies
Two Phase III trials found significantly more patients taking the non-nucleoside reverse transcriptase inhibitor reached undetectable viral load.